Application of Bifidobacterium breve in the preparation of products for treating gastric ulcers and gastric inflammation caused by Helicobacter pylori.
By using the high-yield glycoside hydrolase family 25 protein of Bifidobacterium breve NKU BB1-2 to antagonize Helicobacter pylori, the problem of gastric ulcers and gastritis caused by Helicobacter pylori infection was solved, achieving effective prevention and treatment.
CN121046267BActive Publication Date: 2026-05-26TIANTIANNENG HEALTH IND GRP CO LTD +1
View PDF 4 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- TIANTIANNENG HEALTH IND GRP CO LTD
- Filing Date
- 2025-10-31
- Publication Date
- 2026-05-26
Smart Images
Figure CN121046267B_ABST
Abstract
This invention provides the application of *Bifidobacterium breve* in the preparation of products for treating gastric ulcers and gastric inflammation caused by *Helicobacter pylori*, belonging to the field of microbial technology. The *Bifidobacterium breve* NKU BB1-2 of this invention, with accession number GDMCC NO: 65956, can antagonize *Helicobacter pylori* colonization and alleviate the aggravation of gastric ulcers caused by *Helicobacter pylori*. In vitro, *Bifidobacterium breve* NKU BB1-2 exhibits good antagonistic ability against *Helicobacter pylori*, significantly inhibiting its colonization and growth. Animal experiments show that *Bifidobacterium breve* NKU BB1-2 can alleviate the aggravation of gastric ulcers caused by *Helicobacter pylori* infection in vivo, manifested as reduced gastric mucosal damage, reduced gastric inflammation, and increased gastric pH. Furthermore, *Bifidobacterium breve* NKU BB1-2 can significantly enhance gastric microbial diversity, regulate and improve the gastric microbial structure, and assist in antagonizing and eradicating *Helicobacter pylori* infection.
Need to check novelty before this filing date? Find Prior Art